643 related articles for article (PubMed ID: 26841119)
1. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
2. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
3. Calprotectin more accurately discriminates the disease status of rheumatoid arthritis patients receiving tocilizumab than acute phase reactants.
Inciarte-Mundo J; Ruiz-Esquide V; Hernández MV; Cañete JD; Cabrera-Villalba SR; Ramirez J; Yagüe J; Sanmarti R
Rheumatology (Oxford); 2015 Dec; 54(12):2239-43. PubMed ID: 26242859
[TBL] [Abstract][Full Text] [Related]
4. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
5. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
6. Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Cerezo LA; Mann H; Vencovsky J; Pavelka K; Senolt L
Clin Rheumatol; 2018 Aug; 37(8):2055-2062. PubMed ID: 29656372
[TBL] [Abstract][Full Text] [Related]
7. Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission.
Hurnakova J; Hulejova H; Zavada J; Komarc M; Hanova P; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2016; 11(11):e0165498. PubMed ID: 27832086
[TBL] [Abstract][Full Text] [Related]
8. Calprotectin in rheumatoid arthritis : association with disease activity in a cross-sectional and a longitudinal cohort.
García-Arias M; Pascual-Salcedo D; Ramiro S; Ueberschlag ME; Jermann TM; Cara C; Martín-Mola E; Balsa A
Mol Diagn Ther; 2013 Feb; 17(1):49-56. PubMed ID: 23329363
[TBL] [Abstract][Full Text] [Related]
9. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
10. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
[TBL] [Abstract][Full Text] [Related]
11. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
[TBL] [Abstract][Full Text] [Related]
12. Investigating the link between disease activity and infliximab serum levels in rheumatoid arthritis patients.
Valor L; Hernández-Flórez D; de la Torre I; Del Río T; Nieto JC; González C; López-Longo FJ; Monteagudo I; Llinares F; Rosas J; Garrido J; Naredo E; Carreño L
Clin Exp Rheumatol; 2015; 33(6):805-11. PubMed ID: 26314759
[TBL] [Abstract][Full Text] [Related]
13. Disease activity improvement in rheumatoid arthritis treated with tumor necrosis factor-α inhibitors correlates with increased soluble Fas levels.
Romano E; Terenzi R; Manetti M; Peruzzi F; Fiori G; Nacci F; Bellando-Randone S; Matucci-Cerinic M; Guiducci S
J Rheumatol; 2014 Oct; 41(10):1961-5. PubMed ID: 25179850
[TBL] [Abstract][Full Text] [Related]
14. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
[TBL] [Abstract][Full Text] [Related]
15. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
[TBL] [Abstract][Full Text] [Related]
16. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
Sakellariou G; Lombardi G; Vitolo B; Gomarasca M; Faraldi M; Caporali R; Banfi G; Montecucco C
Clin Exp Rheumatol; 2019; 37(3):429-436. PubMed ID: 30299248
[TBL] [Abstract][Full Text] [Related]
17. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
[TBL] [Abstract][Full Text] [Related]
18. Persistence and dose escalation of tumor necrosis factor inhibitors in US veterans with rheumatoid arthritis.
Cannon GW; DuVall SL; Haroldsen CL; Caplan L; Curtis JR; Michaud K; Mikuls TR; Reimold A; Collier DH; Harrison DJ; Joseph GJ; Sauer BC
J Rheumatol; 2014 Oct; 41(10):1935-43. PubMed ID: 25128516
[TBL] [Abstract][Full Text] [Related]
19. The comparative responsiveness of the patient self-report questionnaires and composite disease indices for assessing rheumatoid arthritis activity in routine care.
Salaffi F; Ciapetti A; Gasparini S; Carotti M; Bombardieri S;
Clin Exp Rheumatol; 2012; 30(6):912-21. PubMed ID: 22935335
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
Hurnakova J; Hulejova H; Zavada J; Hanova P; Komarc M; Mann H; Klein M; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2017; 12(8):e0183420. PubMed ID: 28832684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]